scholarly journals Glial fibrillary acidic protein elevations relate to neuroimaging abnormalities after mild TBI

Neurology ◽  
2018 ◽  
Vol 91 (15) ◽  
pp. e1385-e1389 ◽  
Author(s):  
Jessica Gill ◽  
Lawrence Latour ◽  
Ramon Diaz-Arrastia ◽  
Vida Motamedi ◽  
Christine Turtzo ◽  
...  

ObjectivesTo determine whether a panel of blood-based biomarkers can discriminate between patients with suspected mild traumatic brain injury (mTBI) with and without neuroimaging findings (CT and MRI).MethodsStudy participants presented to the emergency department with suspected mTBI (n = 277) with a CT and MRI scan and healthy controls (n = 49). Plasma concentrations of tau, glial fibrillary acidic protein (GFAP), ubiquitin carboxyl-terminal hydrolase L1, and neurofilament light chain (NFL) were measured using the single-molecule array technology.ResultsConcentrations of GFAP, tau, and NFL were higher in patients with mTBI, compared with those of controls (p's < 0.01). GFAP yielded an area under the curve (AUC) of 0.93 (95% confidence interval [CI] 0.90–0.96), confirming its discriminatory power for distinguishing mTBI from controls. Levels of GFAP, tau, and NFL were higher in patients with trauma-related intracranial findings on CT compared with those with normal CT, with the only significant predictor being GFAP (AUC 0.77, 95% CI 0.70–0.84). Among patients with mTBI, tau, NFL, and GFAP differentiated subjects with and without MRI abnormalities with an AUC of 0.83, with GFAP being the strongest predictor. Combining tau, NFL, and GFAP showed a good discriminatory power (AUC 0.80, 95% CI 0.69–0.90) for detecting MRI abnormalities, even in patients with mTBI with a normal CT.ConclusionOur study confirms GFAP as a promising marker of brain injury in patients with acute mTBI. A combination of various biomarkers linked to different pathophysiologic mechanisms increases diagnostic subgroup accuracy. This multimarker strategy may guide medical decision making, facilitate the use of MRI scanning, and prove valuable in the stratification of patients with brain injuries in future clinical trials.Classification of evidenceClass I evidence that blood concentrations of GFAP, tau, and NFL discriminate patients with mTBI with and without neuroimaging findings.

2019 ◽  
Vol 36 (10) ◽  
pp. 1551-1560 ◽  
Author(s):  
Iftakher Hossain ◽  
Mehrbod Mohammadian ◽  
Riikka S.K. Takala ◽  
Olli Tenovuo ◽  
Linnéa Lagerstedt ◽  
...  

2014 ◽  
Vol 31 (1) ◽  
pp. 19-25 ◽  
Author(s):  
Ramon Diaz-Arrastia ◽  
Kevin K.W. Wang ◽  
Linda Papa ◽  
Marco D. Sorani ◽  
John K. Yue ◽  
...  

2018 ◽  
Vol 26 (2) ◽  
pp. 210-219 ◽  
Author(s):  
Heidi Högel ◽  
Eero Rissanen ◽  
Christian Barro ◽  
Markus Matilainen ◽  
Marjo Nylund ◽  
...  

Background: Cerebrospinal fluid (CSF) levels of two soluble biomarkers, glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL), have been shown to associate with multiple sclerosis (MS) disease progression. Now, both biomarkers can be detected reliably in serum, and importantly, their serum levels correlate well with their CSF levels. Objective: To evaluate the usability of serum GFAP measurement as a biomarker of progressive disease and disease severity in MS. Methods: Clinical course, Expanded Disability Status Scale (EDSS), disease duration, patient age and magnetic resonance imaging (MRI) parameters were reviewed in 79 MS patients in this cross-sectional hospital-based study. Serum samples were collected for measurement of GFAP and NfL concentrations using single molecule array (Simoa) assay. A cohort of healthy controls was evaluated for comparison. Results: Higher serum concentrations of both GFAP and NfL were associated with higher EDSS, older age, longer disease duration, progressive disease course and MRI pathology. Conclusion: Earlier studies have demonstrated that GFAP, unlike NfL, is not increased in association with acute focal inflammation-related nervous system damage. Our work suggests that GFAP serum level associates with disease progression in MS and could potentially serve as an easily measurable biomarker of central nervous system (CNS) pathology related to disease progression in MS.


1999 ◽  
Vol 16 (7) ◽  
pp. 567-581 ◽  
Author(s):  
W. DALTON DIETRICH ◽  
JESSIE TRUETTNER ◽  
WEIZHAO ZHAO ◽  
OFELIA F. ALONSO ◽  
RAUL BUSTO ◽  
...  

2019 ◽  
Vol 47 (6) ◽  
pp. e522-e529 ◽  
Author(s):  
Michèle Shemilt ◽  
Amélie Boutin ◽  
François Lauzier ◽  
Ryan Zarychanski ◽  
Lynne Moore ◽  
...  

2020 ◽  
Vol 11 ◽  
Author(s):  
Nathan A. Huebschmann ◽  
Teemu M. Luoto ◽  
Justin E. Karr ◽  
Ksenia Berghem ◽  
Kaj Blennow ◽  
...  

2004 ◽  
Vol 32 (Supplement) ◽  
pp. A1
Author(s):  
Linda E Pelinka ◽  
Heinz Redl ◽  
Harald Hertz ◽  
Walter Mauritz ◽  
Albert Kroepfl ◽  
...  

Author(s):  
Irina Vasilivna Tsyganenko ◽  
Vasil Vasilyovich Simrok ◽  
Katerina Sergiivna Ruban

The present article is concerned with the study of glial fibrillary acidic protein (GFAP) level in the blood serum of pregnant women  with post–trauma brain injury syndrome (post-TBI syndrome) as the marker of  hematoencephalic barrier status and predictor of obstetric and perinatal complications development.


Sign in / Sign up

Export Citation Format

Share Document